首页> 外文期刊>Research in Pharmaceutical Sciences >Transdermal iontophoretic delivery of celecoxib from gel formulation
【24h】

Transdermal iontophoretic delivery of celecoxib from gel formulation

机译:凝胶制剂对塞来昔布的透皮离子导入

获取原文
           

摘要

Celecoxib is used in the treatment of osteoarthritis, rheumatoid arthritis, acute pain, joint inflammation and sport injuries. Long term administration of the drug results in such complications as gastrointestinaland renal disturbances and cardio-vascular complications. The main objective of the present study was to investigate the feasibility of delivering celecoxib incorporated in gel formulations by iontophoresis. Sodium alginate, sodium carboxymethyl cellulose , hydroxypropyl methylcellulose (HPMC) and carbopol 934P were used to develop topical gel formulations of celecoxib. The gel formulations were evaluated for macroscopic and microscopic properties, pH determination, spreadability, rheological behaviour, and drug release characteristics both in vitro and ex vivo . Drug release was evaluated in the presence of iontophoresis field (0.1 to 0.5 mA/cm 2 ) or without electrical current (passive diffusion) and celecoxib was measured spectrophotometrically at 252 nm. Most gel formulations showed acceptable physicochemical properties. Amongst formulations, gel formulation containing HPMC K4M which indicated greater performance in drug release behaviour was selected for further in vivo studies. The cumulative percent of drug released in vitro at the end of each experiment was 36%, 63%, and 89.7% for passive diffusion, direct electric current (DC) current density of 0.3 mA/cm 2 , and 0.5 mA/cm 2 , respectively. The findings of ex vivo drug transport across rat skin also showed a significantly higher release of celecoxib compared to passive flux for both AC and DC currents. A 0.5 mA/cm 2 of DC current increased drug flux to 73% compared to 41.5% of passive diffusion. It can be concluded from the results of this study that the application of iontophoresis enhances the flux of celecoxib, as compared to the passive diffusion.
机译:塞来昔布用于治疗骨关节炎,类风湿关节炎,急性疼痛,关节发炎和运动损伤。长期服用该药物会导致诸如胃肠道肾功能不全和心血管并发症等并发症。本研究的主要目的是研究通过离子电渗疗法递送结合在凝胶制剂中的塞来昔布的可行性。海藻酸钠,羧甲基纤维素钠,羟丙基甲基纤维素(HPMC)和卡波普934P用于开发塞来昔布的局部凝胶制剂。评价了凝胶制剂的体外和离体的宏观和微观性质,pH值测定,铺展性,流变行为和药物释放特性。在离子电渗疗法场(0.1至0.5 mA / cm 2)或没有电流(被动扩散)的情况下评估药物释放,并在252 nm处用分光光度法测定塞来昔布。大多数凝胶制剂显示出可接受的理化性质。在制剂中,选择了包含HPMC K4M的凝胶制剂以表明其在药物释放性能方面的更高性能,以用于进一步的体内研究。在每个实验结束时,对于被动扩散,0.3 mA / cm 2和0.5 mA / cm 2的直流(DC)电流密度,体外释放的药物累积百分比分别为36%,63%和89.7%。分别。与交流和直流电流的无源通量相比,离体药物在大鼠皮肤中的离体运输结果也表明塞来昔布的释放明显更高。直流电流为0.5 mA / cm 2时,药物通量增加到73%,而被动扩散为41.5%。从这项研究的结果可以得出结论,与被动扩散相比,离子电渗疗法的应用增强了塞来昔布的通量。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号